Philip Bath
Member of Stroke Advisory BoardDr. Philip Bath, BSc, MB, BS, M.D., FRCPath, FRCP, FESC, D. Sc., serves as the Stroke Association Professor of Stroke Medicine at the University of Nottingham. Professor Bath served as a Member of the Clinical Advisory Board at ReNeuron Group plc. He is expert in pharmaceutical studies in stroke at both pre-clinical and clinical level. He is also convener for the Neuroscience@Nottingham and Vascular Research multidisciplinary groups and National Institute for Health Research (NIHR) Associate Director for Industry and Prevention in the Stroke Research Network. With 339 publications, he was the Stroke Association Keynote Lecturer in March 2015. Clinically, he contributes to the NUH Stroke Service (in-patient and out-patient stroke care) and Hypertension Clinic. As an NIHR Senior Investigator, his main research interests cover the treatment of acute stroke (blood pressure lowering), prevention of stroke recurrence and cognitive impairment (antiplatelets, blood pressure and lipid lowering) and enhancement of recovery using stem cells. He uses preclinical studies, clinical trials (phase I to IV) and systematic reviews to help address these questions. He has been Member of Stroke Advisory Board of DiaMedica Therapeutics Inc. (formerly known as DiaMedica Inc.) since 2023 and had been served as a Member of Stroke Clinical Advisory Board. Dr. Bath received his MD from King’s College London, University of London and his DSc from the University of Nottingham.
Positions
- Company NameDiaMedica Therapeutics Inc.Stock CodeDMACPositionMember of Stroke Advisory BoardColleagues
- DJDietrich John PaulsPresident, CEO & Director
- JTJames T. ParsonsIndependent Chairman
- SKScott KellenCFO & Corporate Secretary
- JKJulie KropChief Medical Officer
- ASAmbarish ShahChief Technology Officer
- DRDominic R. CundariChief Commercial Officer
- RMR. Michael GiuffreIndependent Director
- DJDaniel J. O'ConnorIndependent Director
